Innate Pharma S.A. (EPA: IPH)

Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is September - August.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Feb 29, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019
Cash & Equivalents	33	68.15	68.95	36.47	35.13	19.26
Short-Term Investments	110.54	76.54	70.48	67.53	27.52	27.52
Cash & Short-Term Investments	143.54	144.69	139.43	104	62.65	46.78
Cash Growth	-2.03%	3.77%	34.07%	66.00%	33.94%	17.72%
Accounts Receivable	4.1	4.3	3.36	0.92	2	3.05
Other Receivables	2.69	2.02	4.58	2.84	3.32	6.22
Receivables	6.79	6.32	7.94	3.76	5.32	9.27
Inventory	80.08	53.44	37.96	25.51	22.71	27.82
Prepaid Expenses	1.54	-	-	1.9	1.3	1.86
Other Current Assets	6.33	12.41	3.05	0.86	0.9	1.91
Total Current Assets	238.49	217.19	188.74	136.54	93.43	88.39
Property, Plant & Equipment	36.31	36.91	36.9	40.6	38.87	38.85
Long-Term Investments	0.41	0.41	0.41	0	4.82	11.2
Goodwill	32.29	37.28	39.93	38.72	38.72	40.08
Other Intangible Assets	1.17	0.74	2.18	1.58	0.88	1.29
Long-Term Deferred Charges	2.46	2.9	1.47	1.14	1.52	1.41
Other Long-Term Assets	0.33	0.12	0.07	0.05	0.22	0.3
Total Assets	311.56	295.66	269.7	218.63	178.46	181.52
Accounts Payable	36.43	32.23	19.34	15.09	10.22	17.3
Accrued Expenses	17.22	18.38	16.04	15.25	12.25	14.9
Short-Term Debt	7.49	4.26	0.04	0.03	0.01	0.02
Current Portion of Long-Term Debt	5.35	5.17	1.06	26.01	-	-
Current Income Taxes Payable	4.38	3.48	1.58	4.49	1.08	2.36
Current Unearned Revenue	114.24	117.36	117.06	74.68	45.08	40.62
Other Current Liabilities	4.88	1.52	1.33	0.36	1.95	0.83
Total Current Liabilities	189.99	182.4	156.47	135.9	70.59	76.03
Long-Term Debt	14.18	12.05	22.58	1.45	35.56	38.58
Long-Term Leases	4.61	5.11	6.09	7.24	6.82	3.2
Long-Term Unearned Revenue	0.29	4.92	3.75	2.36	2	2.89
Long-Term Deferred Tax Liabilities	0.56	0.18	0.39	0.4	0.68	0.54
Other Long-Term Liabilities	7.18	6.11	7.78	6.63	6.02	5.41
Total Liabilities	218.13	212.15	198.15	155.94	124.02	129.02
Common Stock	1.92	1.92	1.92	1.92	1.92	1.92
Additional Paid-In Capital	5.4	5.4	5.4	5.4	5.4	5.4
Retained Earnings	13.49	11.43	15.91	11.61	7.12	11.05
Comprensive Income & Other	67.47	60.04	47.56	39.03	34.59	27.29
Total Common Equity	88.28	78.79	70.79	57.96	49.02	45.65
Minority Interest	5.14	4.72	0.76	4.73	5.41	6.85
Shareholders' Equity	93.42	83.51	71.55	62.69	54.44	52.5
Total Liabilities & Equity	311.56	295.66	269.7	218.63	178.46	181.52
Total Debt	31.63	26.59	29.77	34.72	42.39	41.8
Net Cash (Debt)	111.91	118.1	109.67	69.28	20.26	4.98
Net Cash Growth	-5.95%	7.69%	58.30%	241.94%	306.93%	-
Net Cash Per Share	67.17	70.88	65.82	41.54	12.15	2.99
Filing Date Shares Outstanding	1.67	1.64	1.65	1.65	1.67	1.67
Total Common Shares Outstanding	1.67	1.64	1.65	1.65	1.67	1.67
Working Capital	48.5	34.79	32.27	0.64	22.84	12.37
Book Value Per Share	53.01	47.93	42.91	35.13	29.41	27.39
Tangible Book Value	54.81	40.77	28.67	17.66	9.42	4.28
Tangible Book Value Per Share	32.91	24.80	17.38	10.70	5.65	2.57
Land	1.91	1.91	1.95	1.95	1.95	1.92
Buildings	31.73	31.73	32.29	33.42	30.18	30.16
Machinery	72.62	70.73	67.04	61.83	57.07	59.89
Construction In Progress	2.5	1.12	2.61	2.66	3.87	1.89

Source: S&P Capital IQ. Standard template. Financial Sources.